Methylmalonic Acidemia Market Size Worth $14.78 Billion By 2032 | CAGR: 5.0%

The global methylmalonic acidemia market size is expected to reach USD 14.78 billion by 2032, according to a new study by Polaris Market Research. The report “Methylmalonic Acidemia Share, Size, Trends, Industry Analysis Report, By Disorder Type (Homocystinuria, Isolated Methylmalonic Acidurias, Combined Methylmalonic Aciduria); By Indication; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Growing consumer awareness of the benefits of methylmalonic acid supplements is expected to drive market growth. A growing number of research studies on the role of methylmalonic acid in various diseases is expected to drive demand for this compound in the coming years. HomoShear Therapeutics blazoned in March 2021 that the oral small patch HST5040 can be used to treat methylmalonic acidemia and propionic acidemia. The IDOL study, a phase 2 trial of HST5040 for the treatment of MMA and PA in cases progressed 2 and over, has begun.

In December 2021, Omega Quant presented the Vitamin B12 Test, containing a sample collection kit that allows for at-home testing. Methylmalonic acidemia is a rare and potentially fatal inheritable complaint that affects about one in every 50,000 newborns. A mutation in the methyl malonyl-CoA mutase gene prevents the body from duly recycling certain fats and proteins in the most common form of MMA.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/methylmalonic-acidemia-market/request-for-sample

The first case was cured on June 2021, according to the company. The trail is anticipated to include seven leading centers in the United States and in Saudi Arabia, The Sunrise trail I originally enrolled 3-12 times old cases with the eventuality to include babies as youthful as 6 months old after meeting certain safety parameters and biomarkers discovery to estimate LB-001 at an early age before unrecoverable damage has passed.

Recurrent infections can be caused by neutropenia during the non-acidotic phase of organic acidemia. It may be unrelated to bone marrow suppression, which is produced by decreased synthesis of these cells as a result of lower pH in the acidotic phase of the illness. More research is needed to determine the influence of pH and the acidic environment on neutrophils, as well as the root cause of neutropenia in patients with organic acidemia.

Methylmalonic Acidemia Market Report Highlights

• Isolated Methylmalonic Acidurias segment is anticipated to grow at a rapid rate as the pathogenic mutations in the gene for methyl malonyl-CoA mutase or in the genes for enzymes involved in the intracellular metabolism of cobalamin can induce isolated methylmalonic aciduria.
• Hyperglycemia accounted for a major global revenue share which is accelerated due to rising disease awareness and increased healthcare spending around the world, the market will grow in size, allowing drug manufacturers to expand their market penetration.
• Hospitals accounted for the largest profit share. The market for hospitals is anticipated to grow significantly over the coming many times as a result of expanding public-private partnerships.
• North America has supremacy in the market due to continuous lifestyle changes, increased healthcare expenditure, and increased availability of funds for research.
• The global players include Biosint, Cayman Chemical, Ceva Sante Animale, Chengda Pharmaceuticals, DSM, John Lee Pharmaceuticals, Merck, Sanofi, Tokyo Chemical Industry, and Lonza group.

Polaris Market Research has segmented the methylmalonic acidemia market report based on Disorder Type, Indication, Distribution Channel, and region:

Methylmalonic Acidemia, Disorder Type Outlook (Revenue - USD Billion, 2019 - 2032)

• Homocystinuria
• Isolated Methylmalonic Acidurias
• Combined methylmalonic Aciduria

Methylmalonic Acidemia, Indication Outlook (Revenue - USD Billion, 2019 - 2032)

• Acidosis
• Ketosis
• Hyperammonemia
• Hypoglycemia
• Hyperglycemia
• Neutropenia
• Other Indications

Methylmalonic Acidemia, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospitals
• Pharmacies
• Clinics
• Others

Methylmalonic Acidemia, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa